Drug Profile
Anti-interleukin 21 monoclonal antibody - Novo Nordisk
Alternative Names: Anti-IL21-Novo-Nordisk; NN-8828; NN-9828; NNC-0114-0000-0005; NNC0114-0006; NNC114-0005Latest Information Update: 21 Feb 2024
Price :
$50
*
At a glance
- Originator ZymoGenetics
- Developer Novo Nordisk
- Class Anti-inflammatories; Antihyperglycaemics; Antirheumatics; Monoclonal antibodies
- Mechanism of Action Interleukin 21 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Crohn's disease; Rheumatoid arthritis; Systemic lupus erythematosus; Type 1 diabetes mellitus
Most Recent Events
- 21 Feb 2024 9410245- Created deal 37240, linked to profile, updated intro, added as sub-licensee, added HE. Indication taken as mentioned in MR as no specific indication was mentioned as per thes. Almirall Pipeline checked, but no info found except this MR
- 19 Feb 2024 NN 8828 licensed to Almirall worldwide for the treatment of Immune inflammatory dermatological diseases
- 30 Oct 2020 Discontinued - Phase-II for Type 1 diabetes mellitus (Combination therapy, Newly diagnosed) in Poland, Belgium, United Kingdom, Denmark, Sweden, Ukraine, Spain, Serbia, Russia, Portugal, Norway, Italy, Israel, Ireland, Finland, Canada, Austria, USA (IV)